Emily Menendez

GU Oncology Now

The phase 3, multicenter, single-arm SPOTLIGHT study <a href="https://aua2021.app.swapcard.com/event/2023-aua-annual-meeting-chicago-il/planning/UGxhbm5pbmdfMTI1Mjk2OA==" target="_blank" rel="noopener">investigated the safety and efficacy</a> of 18F-rhPSMA-7.3, a novel prostate specific membrane antigen-targeting positron emission tomography (PSMA PET) radiopharmaceutical, in patients with prostate cancer with recurrence after primary treatment with radiation therapy.Results of the SPOTLIGHT trial were presented at the American Urological Association 2023 Annual Meeting. Researchers found 18F-rhPSMA-7.3 to have a high affinity and potential for low bladder activity.A total of 389 patients received an evaluable 18F-rhPSMA-7.3 scan. Of those, 76 patients were included in a subgroup to determine the impact of 18F-rhPSMA-7.3 in patients who had received primary treatment with radiation therapy only. Patients underwent PET 50 to 70 minutes after intravenous administration of 296 MBq 18F-rhPSMA-7.3. Scans were evaluated by 3 blinded central readers, with data reported for the individual readers and for the majority read (agreement for =2 readers). Detection rates, including region level analyses, were stratified by the prior treatment.A total of 75 (99%) of the 76 patients had a positive 18F-rhPSMA-7.3 scan, and 32 (42%) patients had positive findings that were confined to the prostate with no further extraprostatic detection. In contrast, 18F-rhPSMA-7.3-avid pelvic nodes were detected in 25% of patients, with distant lesions detected in 43%.High 18F-rhPSMA-7.3 detection rates were observed in the SPOTLIGHT study in patients with intact prostates experiencing prostate cancer recurrence after radiation therapy. While 42% of patients experienced prostate-only recurrence, the finding of 18F-rhPSMA-7.3-avid lesions in distant extrapelvic sites calls for additional research, especially if salvage therapy to the intact prostate is being considered for patients.

SPOTLIGHT Study Results: Novel PSMA PET Radiopharmaceutical Offers Low Bladder Activity

Radioligand therapy prostate-specific membrane antigen

Results of the SPOTLIGHT trial were presented at the AUA 2023 Annual Meeting. 18F-rhPSMA-7.3 has a high affinity and potential for low bladder activity.

Novel PSMA PET Radiopharmaceutical Offers Low Bladder Activity

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe